Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment

被引：3

作者：

McCusker, Michael G. ^{[1
]}

Mehra, Ranee ^{[1
]}

Amr, Sania ^{[1
,2
]}

Taylor, Rodney J. ^{[1
,3
]}

Cullen, Kevin J. ^{[1
]}

Goloubeva, Olga G. ^{[1
,2
]}

机构：

[1] Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[2] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 660 West Redwood St,HH 109, Baltimore, MD 21201 USA

[3] Univ Maryland, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2022年 / 44卷 / 03期

关键词：

chemoradiation; cisplatin and carboplatin; head and neck cancer; overall survival; toxicity; LOCALLY-ADVANCED HEAD; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; RADICAL RADIOTHERAPY; DOSE CISPLATIN; OLDER PATIENTS; CANCER; CHEMOTHERAPY; OROPHARYNGEAL; CARBOPLATIN;

D O I：

10.1002/hed.26965

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Background The best chemoradiation regimen to treat locally and regionally advanced head and neck squamous cell carcinoma (HNSCC) is yet to be established. Methods We compared overall survival (OS) and adverse events following chemoradiation regimens (high-dose [HDC] or low-dose [LDC] cisplatin, or carboplatin [CB]) in HNSCC cases selected from SEER-Medicare linked database. Results Of the 1335 cases who underwent radiotherapy, 264 received HDC, 259 received LDC, and 353 received CB, concurrently. Compared to chemoradiation with HDC, using LDC or CB, or radiotherapy alone were associated with an increasingly worse OS; hazard ratios were 1.33, p = 0.03; 1.35, p = 0.02; and 2.12, p < 0.001; respectively. There were no differences in the rates of adverse events between the three chemoradiation regimens. Conclusion Chemoradiation regimen using HDC appears to be the best primary treatment for locally and regionally advanced HNSCC. Nonetheless, prospective large studies are warranted to further determine its absolute benefit.

引用

页码：749 / 759

页数：11

共 40 条

[1] Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].

Adelstein, DJ ;

Li, Y ;

Adams, GL ;

Wagner, H ;

Kish, JA ;

Ensley, JF ;

Schuller, DE ;

Forastiere, AA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98

[2] The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma [J].

Al-Mamgani, A. ;

de Ridder, M. ;

Navran, A. ;

Klop, W. M. ;

de Boer, J. P. ;

Tesselaar, M. E. .

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2017, 274 (10) :3757-3765

[3] Treatment modalities, adverse events, and survival outcomes in older patients with head and neck squamous cell carcinoma [J].

Amr, Sania ;

Ioffe, Dina ;

Suzuki, Ikumi ;

Mehra, Ranee ;

Cullen, Kevin ;

Goloubeva, Olga .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2021, 43 (12) :3935-3945

[4] The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments [J].

Austin, Peter C. .

STATISTICS IN MEDICINE, 2014, 33 (07) :1242-1258

[5] CONCURRENT CHEMORADIATION WITH CARBOPLATIN-5-FLUOROURACIL VERSUS CISPLATIN IN LOCALLY ADVANCED OROPHARYNGEAL CANCERS: IS MORE ALWAYS BETTER? [J].

Barkati, Maroie ;

Fortin, Bernard ;

Soulieres, Denis ;

Clavel, Sebastien ;

Despres, Phillipe ;

Charpentier, Danielle ;

Tabet, Jean-Claude ;

Guertin, Louis ;

Olivier, Marie-Jo ;

Coulombe, Genevieve ;

Donath, David ;

Nguyen-Tan, Phuc Felix .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (02) :410-416

[6] Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck [J].

Bauml, Joshua M. ;

Vinnakota, Ravi ;

Park, Yeun-Hee Anna ;

Bates, Susan E. ;

Fojo, Tito ;

Aggarwal, Charu ;

Limaye, Sewanti ;

Damjanov, Nevena ;

Di Stefano, Jessica ;

Ciunci, Christine ;

Genden, Eric M. ;

Wisnivesky, Juan P. ;

Ferrandino, Rocco ;

Mamtani, Ronac ;

Langer, Corey J. ;

Cohen, Roger B. ;

Sigel, Keith .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (05) :490-497

[7] Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer [J].

Bernier, J ;

Domenge, C ;

Ozsahin, M ;

Matuszewska, K ;

Lefèbvre, JL ;

Greiner, RH ;

Giralt, J ;

Maingon, P ;

Rolland, F ;

Bolla, M ;

Cognetti, F ;

Bourhis, J ;

Kirkpatrick, A ;

van Glabbeke, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1945-1952

[8] Association of Type of Treatment Facility With Overall Survival After a Diagnosis of Head and Neck Cancer [J].

Carey, Ryan M. ;

Fathy, Ramie ;

Shah, Ravi R. ;

Rajasekaran, Karthik ;

Cannady, Steven B. ;

Newman, Jason G. ;

Ibrahim, Said A. ;

Brant, Jason A. .

JAMA NETWORK OPEN, 2020, 3 (01)

[9] Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck [J].

Cooper, JS ;

Pajak, TF ;

Forastiere, AA ;

Jacobs, J ;

Campbell, BH ;

Saxman, SB ;

Kish, JA ;

Kim, HE ;

Cmelak, AJ ;

Rotman, M ;

Machtay, M ;

Ensley, JF ;

Chao, KSC ;

Schultz, CJ ;

Lee, N ;

Fu, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1937-1944

[10] Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma [J].

Denis, F ;

Garaud, P ;

Bardet, E ;

Alfonsi, M ;

Sire, C ;

Germain, T ;

Bergerot, P ;

Rhein, B ;

Tortochaux, J ;

Calais, G .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :69-76

← 1 2 3 4 →